CGH
LGND icon

Crossmark Global Holdings’s Ligand Pharmaceuticals LGND Stock Holding History

Crossmark Global Holdings’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Sell
2,148
-244
-10% -$57.5K 0.01% 763
2026
Q1 		$478K Buy
2,392
+128
+6% +$25.3K 0.01% 840
2025
Q4 		$428K Buy
2,264
+456
+25% +$87.6K 0.01% 895
2025
Q3 		$320K Buy
1,808
+48
+3% +$7.14K ﹤0.01% 1070
2025
Q2 		$200K Buy
+1,760
New +$188K ﹤0.01% 1277
2024
Q3 		– Sell
-7,088
Closed -$597K – 1316
2024
Q2 		$597K Buy
7,088
+85
+1% +$6.76K 0.01% 753
2024
Q1 		$512K Buy
+7,003
New +$516K 0.01% 859
2022
Q1 		– Sell
-2,706
Closed -$261K – 1367
2021
Q4 		$261K Buy
2,706
+369
+16% +$34.1K 0.01% 1217
2021
Q3 		$203K Buy
+2,337
New +$181K ﹤0.01% 1347
2021
Q2 		– Sell
-2,318
Closed -$220K – 1428
2021
Q1 		$220K Buy
+2,318
New +$219K 0.01% 1332
2020
Q4 		– Sell
-5,139
Closed -$306K – 1413
2020
Q3 		$306K Sell
5,139
-177
-3% -$12.1K 0.01% 1012
2020
Q2 		$371K Buy
5,316
+113
+2% +$7.16K 0.01% 894
2020
Q1 		$236K Sell
5,203
-80
-2% -$4.53K 0.01% 978
2019
Q4 		$344K Buy
5,283
+1,394
+36% +$93.2K 0.01% 1031
2019
Q3 		$241K Sell
3,889
-240
-6% -$15.1K 0.01% 1173
2019
Q2 		$294K Sell
4,129
-454
-10% -$33.4K 0.01% 1113
2019
Q1 		$359K Buy
4,583
+32
+0.7% +$2.42K 0.01% 1019
2018
Q4 		$385K Sell
4,551
-513
-10% -$54.7K 0.01% 899
2018
Q3 		$867K Sell
5,064
-335
-6% -$50.5K 0.02% 666
2018
Q2 		$698K Buy
5,399
+260
+5% +$29K 0.02% 752
2018
Q1 		$530K Sell
5,139
-257
-5% -$25.4K 0.01% 885
2017
Q4 		$461K Buy
5,396
+390
+8% +$33.8K 0.01% 1055
2017
Q3 		$425K Buy
+5,006
New +$396K 0.01% 1070
2016
Q3 		$425K Buy
+5,006
New +$368K 0.01% 1070

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crossmark Global Holdings's LGND Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Ligand Pharmaceuticals (LGND) stake by 10% in Q2 2026, selling an estimated $57.5K and leaving 2,148 shares worth $679K. The position accounts for 0.01% of the portfolio, ranked #763.

Crossmark Global Holdings first reported a position in LGND in Q3 2016 and has held it in 24 quarters since. The position peaked at $867K in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Crossmark Global Holdings held 2,148 shares of Ligand Pharmaceuticals worth $679K as of Q2 2026.
  • Crossmark Global Holdings sold 244 Ligand Pharmaceuticals shares in Q2 2026, an estimated $57.5K.
  • Ligand Pharmaceuticals made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #763 holding.
  • Crossmark Global Holdings first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 24 quarters since.
  • Crossmark Global Holdings's Ligand Pharmaceuticals position peaked at $867K in Q3 2018.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.